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Abstract
Diabetes mellitus is becoming increasingly prevalent worldwide. Additionally, there is an increasing number of 
patients receiving implantable devices such as glucose sensors and orthopedic implants. Thus, it is likely that 
the number of diabetic patients receiving these devices will also increase. Even though implantable medical 
devices are considered biocompatible by the Food and Drug Administration, the adverse tissue healing that 
occurs adjacent to these foreign objects is a leading cause of their failure. This foreign body response leads 
to fibrosis, encapsulation of the device, and a reduction or cessation of device performance. A second adverse event 
is microbial infection of implanted devices, which can lead to persistent local and systemic infections and also 
exacerbates the fibrotic response. Nearly half of all nosocomial infections are associated with the presence of an 
indwelling medical device. Events associated with both the foreign body response and implant infection can 
necessitate device removal and may lead to amputation, which is associated with significant morbidity and 
cost. Diabetes mellitus is generally indicated as a risk factor for the infection of a variety of implants such as 
prosthetic joints, pacemakers, implantable cardioverter defibrillators, penile implants, and urinary catheters. 
Implant infection rates in diabetic patients vary depending upon the implant and the microorganism, however, 
for example, diabetes was found to be a significant variable associated with a nearly 7.2% infection rate for 
implantable cardioverter defibrillators by the microorganism Candida albicans. While research has elucidated many 
of the altered mechanisms of diabetic cutaneous wound healing, the internal healing adjacent to indwelling 
medical devices in a diabetic model has rarely been studied. Understanding this healing process is crucial 
to facilitating improved device design. The purpose of this article is to summarize the physiologic factors 
that influence wound healing and infection in diabetic patients, to review research concerning diabetes and 
biomedical implants and device infection, and to critically analyze which diabetic animal model might be 
advantageous for assessing internal healing adjacent to implanted devices.
J Diabetes Sci Technol 2011;5(3):605-618
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Introduction
In 2007, the American Diabetes Association estimated 
nearly 25 million people were affected by diabetes in 
the United States.1 A considerable number of these 
individuals will require some sort of indwelling medical 
device in their lifetime as the use of devices such as 
orthopedic implants, breast implants, and glucose sensors 
is rapidly expanding. In 2004, 600,000 joint prostheses 
and 2,000,000 fracture-fixation devices were implanted 
in the United States. Breast implants accounted for 130,000 
implanted medical devices (Table 1), while statistics 
estimated that nearly 800,000 dental implants were done 
in the United States in 2004.3 As the percentage of the 
population affected by diabetes increases, a larger fraction 
of these implanted devices will be placed in diabetes 
patients. Specifically, percutaneous glucose sensors are 
designed for use in diabetic patients. Medtronic, Inc., 
which manufactures the MiniMed glucose sensor, has 
sold over one million sensors as of 2008, which have 
been implanted in patients worldwide.4
Performance of biomedical implants has been hindered 
by fibrosis, infections, and deficient tissue integration 
due in part to the body’s foreign body response. 
Implant-associated infections account for half of the 
nearly 2 million nosocomial infections in the United 
States yearly.5 While most of these infections involve 
catheters, infections involving surgical implants are 
generally more difficult to manage because they usually 
require a longer period of antibiotic therapy and repeated 
surgical procedures.2,6,7 Concerning glucose sensors, while 
there is no reported research on the infection rates of 
such devices, infection is a potential concern due to 
the tract available for bacterial migration. Some groups 
have engineered coatings for glucose sensors to prevent 
or mediate bacterial infection. The Schoenfisch group 
has coated glucose sensors with nitric oxide-releasing 
xerogels, which have antibacterial properties.8 In addition, 
device function and performance can be adversely affected 
if the foreign body response elicited by the device 
culminates in fibrotic encapsulation.
Additionally, common complications of diabetes are 
altered healing of wounds and a higher susceptibility 
to infections.9,10 These deficiencies can complicate the 
body’s acceptance of an implant and lead to greater 
rates of rejection. While some research has investigated 
the effect of diabetes on the body’s healing ability, most 
particularly the case of diabetic foot ulcers, these findings 
have not been applied to understanding a diabetic 
patient’s response to an indwelling implant. Few examples 
discuss the prevalence of infection in diabetic patients 
with indwelling implants or even the ability of a diabetic 
patient to receive such implants. However, the prevalence 
of diabetes and the increasing use of indwelling medical 
devices warrant such investigation.
Many physiologic factors contribute to wound healing 
deficiencies in diabetic patients. Many studies have 
implicated a decreased inflammatory response consisting 
of decreased or impaired growth factor production 
and decreased neutrophil and macrophage function. 
During later stages of wound repair, diabetic patients 
exhibit decreased and less organized granulation tissue 
formation, poor angiogenic response, and altered collagen 
Table 1.
Clinical and Economic Consequences of Infections Associated with Surgical Implantsa
Implant type Implants inserted in the US anually
Projected infections 
of implants annually
% first implant 
infection rate
Preferred no. of 
stages for surgical 
replacement
Estimated cost of each 
med + surgical treatment
Cardiovascular
Vascular grafts 450,000 16,000 4 1 $40,000
Pacemaker 300,000 12,000 4 2 $35,000
Orthopedic
Joint prostheses 600,000 12,000 2 2 $30,000
Fracture-fixation device 2,000,000 100,000 5 1 or 2 $15,000
Plastic – breast (pair) 130,000 2,600 2 2 $20,000
a Only >100,000 implants; adapted from New England Journal of Medicine2
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deposition and organization.11 Also, diabetic wounds 
are characterized by nitric oxide (NO) deficiency, which 
has negative effects on the wound healing response as well 
as the response to infection.12
Little research has focused on how diabetes alters the 
internal wound healing around an implant. In normal 
tissues, the presence of an implant leads to the foreign 
body reaction and eventual fibrotic encapsulation. 
Few studies have attempted to determine if a similar 
response occurs in diabetic patients. Studies that focus 
solely on the diabetic response to a biomedical implant 
are essential to improving device performance in 
these patients.
Diabetic patients are generally more susceptible to 
infections, which presents a significant obstacle to 
implant integration. Infections result in considerable 
morbidity and mortality in diabetic patients even in 
the absence of an indwelling medical device. In a study 
conducted by Bertoni and colleagues, 9,208 adults aged 
30–74 years in 1976–1980 were followed over a period 
of 12–16 years. Thirty-six infection-related deaths occurred 
among 533 diabetic adults versus 265 deaths in 8,675 
adults without diabetes (4.7 vs 1.5 per 1,000 person-years, 
p < .001), suggesting that diabetic adults are at greater 
risk for infection-related mortality.13 In the presence of an 
implant, several large-scale retrospective studies have 
found diabetes patients have increased rates of surgical site 
infections when compared to healthy individuals.14–17 
In diabetic patients undergoing spondylolithesis, the 
rate of infection was 10.3% compared to 0.7% in 
nondiabetic patients.15 Extensive research has been 
done to elicit the differences in infection response in 
diabetic and nondiabetic patients, with most studies 
suggesting defects in cellular innate immunity as being 
primarily responsible for the decreased ability to fight 
infection. Additionally, some studies have shown certain 
microorganisms exhibit an increased adherence to diabetic 
cells.10,18 Understanding the diabetic response to infection 
can be useful in improving implanted device longevity.
Many therapies have been developed to address the 
deficiencies present in the diabetic wound. Treatments 
include NO supplementation in the diabetic wound and 
growth factor therapy. Molsidomine, an orally active, long-
acting vasodilating drug, spontaneously releases NO 
and was found to increase wound breaking strength in 
diabetic wounds.12 Treatment with recombinant human 
growth factors such as platelet-derived growth factor 
(PDGF) and basic fibroblast growth factor (FGF) has 
been shown to increase fibroblasts and capillaries at 
the wound site and promote greater closure of diabetic 
wounds.19 Additionally, vascular endothelial growth 
factor (VEGF) production in a diabetic wound can be 
stimulated by administering simvastatin (ZOCOR®), a drug 
typically used to reduce cholesterol. Simvastatin-treated 
wounds showed greater amounts of VEGF protein 
expression and increased angiogenesis.20
Animal research has been instrumental in understanding 
the mechanisms and complications of diabetic wound 
healing. Several models exist that accurately reflect 
aspects of both type 1 and type 2 diabetes. Certain drugs 
can induce type 1 diabetes by damaging pancreatic 
beta cells. Alternatively, genetic models are produced by 
selective inbreeding to develop hyperglycemia and other 
related traits such as obesity, immune deficiency, or 
insulin resistance. Owing to the complexity of diabetes, 
new models are continually being developed and studies 
involving transgenic and humanized models are becoming 
more prevalent.
Molecular Pathogenesis of Wound Healing 
in Diabetes Patients
Over 100 physiologic factors have been discovered that 
contribute to wound healing deficiencies in diabetic 
patients.11 Such factors include impaired growth factor 
production,21–23 angiogenic response,23,24 macrophage 
function,25 collagen accumulation, quantity of granulation 
tissue,23 fibroblast migration and proliferation, number of 
epidermal nerves,26 and balance between extracellular 
matrix (ECM) component accumulation and remodeling 
by matrix metalloproteinases (MMPs).27 In normal tissues,
wound healing is characterized by efficient inflammatory 
cell recruitment in response to a variety of chemokines, 
including macrophage inflammatory protein 2 (MIP-2) and 
monocyte chemotactic protein 1 (MCP-1). Chemokine and 
cytokine signaling stimulate the production of growth 
factors that promote matrix formation, angiogenesis, and 
reepithelialization (Figure 1). In diabetic wounds, however, 
decreased chemokine expression results in decreased 
growth factor production and delayed inflammatory cell 
infiltration.28 Alterations in many chemokines and growth 
factors in diabetic wounds lead to impairments in 
angiogenesis, matrix formation, and reepithelialization 
(Table 2), deficiencies that are detrimental not only to 
cutaneous wounds but also to internal wounds adjacent 
to surgical implants.28,29 During later stages of diabetic 
wound healing, persistence of inflammatory cells within 
injured tissue results in continued damage and turnover 
due to increased expression of interleukin-1b (IL-1b), 
tumor necrosis factor a (TNF-a), and MMPs.29
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Figure 1. Normal wound healing and alterations in diabetic wounds. IGF-1, insulin-like growth factor 1; KGF, keratinocyte growth factor. 
Reprinted with permission from Vascular.28
Table 2.
Changes in Expression of Cytokines and Growth Factors in Diabetic Wound Healinga
a Reprinted with permission from International Wound Journal29
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Other aspects of diabetic wound healing include reduced 
cell proliferation in the wound tissue, slowed onset of 
myofibroblast differentiation, and increased levels of 
apoptosis during inappropriate stages of the healing 
process.30 Keratinocytes show an absence of migration, 
hyperproliferation, and incomplete differentiation while 
fibroblasts exhibit decreased migration and proliferation.
Some of these factors are particularly of significance in 
the tissue integration of an indwelling medical device. 
Decreased amounts of VEGF and other growth factors 
influence the development of blood vessels crucial to 
proper wound healing; poor angiogenesis results in 
poor implant integration with surrounding tissue.31–33 
Decreased capillary concentration around an implant 
results in poorly perfused tissue that is inconsistent with 
healthy tissue. Additionally, diabetic wound sites were 
found to be stiffer due to greater collagen accumulation 
and cross-linking, and decreased amounts of growth 
factors such as PDGF and epidermal growth factor result 
in poor matrix formation.29,31 Finally, NO, an important 
mediator in wound healing, is deficient in diabetic 
wounds.12 In addition to its role in wound healing, NO 
has antibacterial properties that can partly assist in 
combating implant-associated infections.34
Mechanisms of Wound Healing in Healthy 
People vs People with Diabetes
Wound healing is a complex cellular response to injury 
and involves the activation of keratinocytes, fibroblasts, 
endothelial cells, macrophages, and platelets. These cells 
release growth factors, cytokines, and chemokines that 
coordinate and maintain healing in healthy individuals. 
Shortly after injury, hypoxia is induced and VEGF released 
by macrophages, fibroblasts, and epithelial cells initiates 
the phosphorylation and activation of endothelial nitric 
oxide synthase (eNOS) in the bone marrow. Rising NO 
levels initiate the mobilization of bone marrow endo-
thelial progenitor cells (EPCs) to the circulation. 
Chemokines direct these EPCs to the wound site where 
they participate in vasculogenesis.
According to a murine model of diabetes,11 eNOS 
phosphorylation in the bone marrow is impaired as 
evidenced by significantly limited EPC migration from 
the bone marrow into the circulation. In addition to 
deficient activation of eNOS, expression of key chemokines 
is decreased in epithelial cells and myofibroblasts of the 
diabetic model. EPCs do not receive the signals necessary 
to relocate to the wound site, and healing is impaired 
due to decreased angiogenesis (Figure 2).
Diabetes and the Time Course of Wound 
Healing
Much of what is known about diabetic wound healing 
has been derived from experimental wounds in animals. 
The biological and molecular events occurring after 
cutaneous injury are generally divided into four phases of 
repair: coagulation, inflammation, migration-proliferation 
and matrix deposition, and remodeling (Figures 3 and 4). 
The phases overlap considerably but healthy wounds 
exhibit linear progression. Conversely, chronic nonhealing 
wounds such as those often seen in diabetic patients have 
a disorganized progression of wound healing, with some 
wound areas present in different phases simultaneously.
The Course of Normal Wound Healing
During coagulation, the first phase of wound healing, a 
fibrin plug forms shortly after injury and inflammatory 
cells quickly migrate to the wound. Platelets within the 
plug release growth factors such as PDGF and transforming 
growth factor b (TGF-b) that are responsible for cell 
recruitment. Although hypoxia results from damage 
to blood vessels, beneficial effects include increased 
keratinocyte migration, early angiogenesis, proliferation 
and expansion of fibroblasts, and transcription and 
synthesis of necessary growth factors and cytokines. 
These processes occur within hours of injury.
During inflammation, which takes place within about 
2–3 days after injury, neutrophils and monocytes arrive 
and assist in wound debridement and release growth 
factors. Several other inflammatory and dermal cells 
follow including macrophages, fibroblasts, and endothelial 
cells. Granulation tissue begins to form.
Occurring over several days after injury, the migration-
proliferation phase is marked by epidermal resurfacing, 
fibroplasia, angiogenesis, ECM deposition, and initial 
wound contraction. Contraction is promoted by the 
formation and organization of granulation tissue and the 
presence of myofibroblasts. Angiogenesis supplies the 
wound area with oxygen and nutrients. In the weeks and 
months after injury, a scar is formed at the wound site 
that is remodeled over time. ECM degrades and further 
contraction occurs.23,35
In diabetic patients, all stages of the wound healing 
cascade are affected. Many studies have shown a 
decreased inflammatory response in diabetic wounds, 
including decreased chemotaxis, bacterial killing and 
phagocytosis, and antioxidant levels resulting from the 
impaired function of neutrophils and macrophages.12,36–38 
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Figure 2. Mechanisms of wound healing in healthy people versus people with diabetes. HBO, hyperbaric oxygen therapy; SDF-1, stromal cell-
derived factor-1. Reprinted with permission from The Journal of Clinical Investigation.11
Figure 3. The time course of the different cells appearing in the 
wound during the healing process. Macrophages and neutrophils 
are predominant during inflammation, whereas lymphocytes 
peak somewhat later and fibroblasts are predominant during the 
proliferative phase. Reprinted with permission from Surgical Clinics of 
North America.35
Figure 4. Phases of wound healing, major types of cells involved in 
each phase, and selected specific events. Reprinted with permission 
from Lancet.23
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During later stages of healing, diabetic wounds show growth 
factor depletion,39,40 raised glucocorticoid concentrations,41 
diminished cell proliferation,42,43 and increased apoptosis.30 
Several days after injury, neovascularization is decreased 
and granulation tissue is poorly developed.44 The alterations 
in cell recruitment and proliferation seen in diabetes may 
complicate integration of implanted devices; decreased 
granulation tissue formation likely results in an unstable 
environment for a device. Additionally, poor blood vessel 
development and perfusion may result in the formation 
of an avascular tissue barrier around a device when 
optimally the area around an implant should be identical 
to uninjured tissue. In particular, decreased neovascu-
larization is a considerable impediment to the function 
of glucose sensors, as distance from the sensor to glucose 
in the bloodstream can affect the accuracy of glucose 
measurements.
Diabetes and Biomedical Implants
In normal tissues, the presence of an implant can lead 
to the foreign body reaction and eventual fibrotic 
encapsulation, which can severely limit the device’s 
performance. For example, fibrotic encapsulation of glucose 
sensors prevents accurate measurements of blood glucose 
levels because glucose must diffuse through an abnormal 
tissue barrier before its concentration can be read by 
the sensor. The ensuing lag time results in different 
concentrations in the blood and at the sensor surface. 
It is unknown if a similar foreign body response occurs 
in diabetic patients.
Considerable research has focused on dental and 
orthopedic implants in diabetic patients, however, these 
implants are atypical of soft tissue implants. With regards 
to soft tissue implants, subcutaneous and percutaneous 
devices of varying materials have been implanted in 
diabetic animal models to study the wound healing 
response—not necessarily to the implanted device. 
Additionally, implants releasing therapeutic agents such 
as NO have been reported12 but these studies emphasize 
techniques to enhance wound healing in diabetic patients. 
Therefore, it is crucial to study implant healing in 
diabetic patients because understanding how the foreign 
body reaction is regulated in diabetic patients will allow 
for the development of new therapies to reduce fibrosis 
and increase the utility of implanted devices.
Dental and Orthopedic Implants
Several experimental models have investigated the effect 
of diabetes on the osseointegration of dental and 
orthopedic implants.45 Periodontal disease is a frequent 
complication of diabetes. The failure rate of bone 
implants is higher in diabetic patients, particularly if the 
disease is poorly controlled. Studies have shown that 
diabetes induces an alteration in the bone remodeling 
processes. Deficient mineralization then results in decreased 
osseointegration of the implant. Reduction in contact 
between the bone and the implant is present despite 
comparable bone formation in diabetic and control animal 
models and infection of oral implants is a continual 
danger. Antibiotics are often recommended for diabetic 
patients because of their greater susceptibility to infection.
In the orthopedic literature, research examining differential 
healing in diabetic animal models has focused primarily 
on bone fractures because, clinically, diabetes has been 
shown to alter bone composition, reduce bone mass, and 
impair fracture healing in humans.46 The mechanism 
of delayed bone healing in diabetic animal models has 
yet to be fully elucidated, but impaired osteoblast47 and 
osteoclast48 function as well as altered chondrogenesis49 
have been proposed.
Subcutaneous Implants
One study31 investigated wound healing in a diabetic 
baboon model using a polystyrene implant. Drum devices 
were implanted subcutaneously in the thighs of long-term 
diabetic baboons. Implants were removed after 2 and 4 
weeks and analyzed for granulation tissue and inflam-
matory cell migration into the drums. Granulation tissue 
was reduced at both time points in diabetic baboons and 
vessel lumen areas were greater at 4 weeks compared 
to control animals. Fewer macrophages were present in 
diabetic tissue while neutrophils were prominent. Lastly, 
after 4 weeks, diabetic wound tissue exhibited less 
connective tissue ingrowth, resulting in a coarser, more 
disorganized tissue structure. There was no mention of 
fibrotic capsule formation.
Percutaneous Implants
Gerritsen and colleagues50 investigated the soft tissue 
response to subcutaneous and percutaneous devices 
composed of titanium fiber mesh in diabetic and non-
diabetic rabbits. The percutaneous device consisted of 
a subcutaneous component of titanium fibers and a 
percutaneous segment that was attached via a threaded 
hole. Titanium mesh was also implanted subcutaneously 
to examine the difference in tissue response to 
subcutaneous and percutaneous implants. The group 
found a greater number of infectious complications around 
percutaneous implants in severely diabetic animals. 
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Severe diabetes adversely affected matrix maturation 
and delayed neovascularization in both implant types. 
Inflammatory cells were present in higher numbers around 
percutaneous devices in severely diabetic rabbits; a nearly 
40% increase in inflammatory cells was seen around these 
devices when compared to the subcutaneous devices.
Diabetes and Infection
Patients with diabetes are more susceptible to infections. 
Infections are responsible for considerable morbidity and 
mortality in diabetic patients and thus understanding 
the deficiencies that lead to infection susceptibility is a 
crucial area of research. Many causes may play a role, 
including defects in immunity, an increased adherence 
of microorganisms to diabetic cells, and the elevated 
number of medical interventions among diabetic 
patients.10,18 The risk of infection in diabetic patients is 
a significant obstacle to proper integration of a medical 
device. Nearly half of all nosocomial infections in the 
United States are associated with an indwelling device; 
approximately 200,000 of these infections will involve 
surgical implants as opposed to indwelling catheters.4,5 
By investigating the diabetic response to infection in the 
absence and presence of an indwelling implant, factors 
may be identified that contribute to increased infection 
susceptibility and guide improved implant integration.
The Normal Immune Response to Infection
The normal immune response in wound healing can 
be divided into the innate and the adaptive immune 
response. The repeated observations in other publications 
suggest that only the innate response is adversely altered 
in diabetic foreign body reaction.
In the innate response, cells such as T cells, natural 
killer cells, neutrophils, mast cells and macrophages 
immediately recognize an antigen and attack the carrier 
in a nonspecific manner. The response is short-lived 
and does not confer lasting, protective immunity to the 
host.48 Innate immunity provides immediate defense 
against infection by recruiting immune cells via cytokine 
signaling, assisting in the activation of the complement 
cascade, identifying and removing foreign substances, 
and activating the adaptive immune system through 
antigen presentation. Many studies have implicated the 
following constituent factors of the innate immune system 
as being most responsible for the alterations in diabetic 
healing: defects in polymorphonuclear leukocytes (PMNLs), 
altered monocytes and mast macrophages, and increased 
adherence of microorganisms to diabetic cells.
The adaptive immune system consists of specialized 
systemic cells and processes that eliminate or prevent 
pathogenic challenges. The adaptive immune system is 
activated by the innate immune system and provides 
the ability to recognize and remember specific pathogens. 
Future infection by those pathogens will result in a 
stronger immune response. The humoral aspect of 
the adaptive immune system is mediated by secreted 
antibodies produced by B cells. Antibodies bind to antigen 
markers on the surfaces of invading microbes such as 
viruses or bacteria, which flags them for destruction.
The adaptive humoral immune response is the main 
defense against invasion of extracellular bacteria. 
Production of antibodies assists in the removal of bacteria 
and the inactivation of bacterial toxins. Antibodies that 
bind to available antigens on the surface of bacteria assist 
in activating the complement cascade, resulting in 
increased phagocytosis, clearance, and localized production 
of immune effector molecules that assist in the inflam-
matory response. Effector molecules such as C3a and 
C5a function as anaphylatoxins to promote local mast-
cell degranulation, vasodilation, and extravasation of 
lymphocytes and neutrophils from the blood into the 
tissue. Other complement products act as chemotactic 
factors for neutrophils and macrophages, increasing the 
number of phagocytic cells at the infection site.
Immune Deficiencies in a Diabetic Patient
Deficiencies in diabetic patients appear to occur primarily 
within the innate immune system. For instance, adaptive 
humoral immunity in diabetic patients expresses normal 
levels of serum antibodies and normal response to 
vaccinations.18,51–53 In adaptive cellular immunity, the 
proliferative response of lymphocytes in diabetic patients 
is inhibited with some stimuli, such as Staphylococcus aureus 
and phytohemagglutinin, and normal with others.10 
However this alteration does not appear to enhance 
infection susceptibility in diabetic patients.
Defects in Cellular Innate Immunity
Cellular Innate Immunity: Defects in PMNLs
Studies involving PMNLs in diabetic patients have reported 
abnormalities in the adherence, chemotaxis, phagocytosis, 
oxidative properties, and intracellular killing of these 
cells.10 Reportedly, PMNL chemotaxis is significantly 
lower in diabetic patients even after stimulation when 
compared to controls.54 In addition, PMNL phagocytotic 
and killing capacity has been found to be lower in diabetic 
patients (Table 3), leading to a poorer ability to fight off
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infection. The pathogenesis of these abnormalities is not 
entirely known, and conflicting studies have emerged. 
It also seems that proper glucose control can rectify these 
immune deficiencies so the true influence of PMNL defects 
on infection susceptibility is still uncertain.18
Cellular Innate Immunity: Defects in Monocytes/Macrophages
Diabetic monocytes exhibit both impaired chemotaxis 
and phagocytosis most likely resulting from an intrinsic 
monocyte defect. One study showed that children with 
type 1 diabetes had a lower immune response to 
intradermal administration of hepatitis B vaccine when 
compared with control children. In this case, defective 
macrophage function appeared to be responsible.53
Adherence of Microorganisms to Diabetic Cells
Microorganism adherence to mucosal or epithelial cells is 
an early step in the pathogenesis of infections. C. albicans 
is an infectious microorganism commonly found in 
diabetic patients. Researchers determined several risk 
factors that could increase the risk of contracting the 
infection in diabetic patients, including a lower age, 
higher hemoglobin A1c level, the presence of glucosuria, 
and cigarette smoking. It is theorized that poor regulation 
of high blood glucose levels and other factors lead to 
altered receptors on the patient’s cells that exhibit greater 
adherence for infectious organisms.18
Immune Dysfunction and Infection Response in 
Diabetic Animal Models
Animal models have played a key role in the attempt 
to elucidate the mechanism of immune dysfunction 
in diabetic patients. Although these findings are not 
broadly applicable, if taken into proper context, they can 
provide useful insight into the underlying physiology. 
Leukocyte dysfunction in diabetic animals has been 
studied extensively, and the decreased inflammatory 
response observed in diabetic rodents has been attributed 
to many factors including a decreased microvascular 
response to histamine and bradykinin, reduced mast cell 
degranulation, and reduced levels of TNF-α and IL-1.55 
Additionally, diabetic rodents infected with S. aureus 
have shown altered neutrophil chemotaxis and decreased 
production of reactive oxygen species.56 Macrophage 
dysfunction in streptozotocin-induced diabetic rats has 
also been studied, showing that mice with prolonged 
uncontrolled diabetes have decreased cytokine production, 
antigen presentation, and phagocytosis.57
Enhancing Wound Healing in Diabetes: 
Experimental Therapies
Many therapies have been developed to address deficiencies 
present in the diabetic wound. Most experimental healing 
therapies have been applied to skin incisions of varying 
thickness; studies have investigated healing of these 
incisions in a variety of animal models from mice 
to baboons.20,31 Other studies involve subcutaneous 
implants that can release healing promoters such as 
NO.12 These various treatments have shown promise 
in some animal models but not all have been attempted 
in human patients.
Nitric Oxide Supplementation in the Diabetic 
Wound
Diabetic wounds are characterized by NO deficiency. 
One group12 developed a method for delivering NO 
donor to the wound site. Polyvinyl alcohol sponges were 
implanted subcutaneously through dorsal skin incisions 
created in diabetic and nondiabetic rats. Half of the 
implants were treated with the NO donor molsidomine. 
The study found that wound breaking strength and 
MMP-2 activity were significantly increased by exogenous 
NO. Nitric oxide treatment, however, had no effect on 
the delayed inflammatory reaction in diabetes. The results 
Table 3.
Summary of the Different Immune Dysfunctions Found in Diabetic Patientsa
a Reprinted with permission from FEMS Immunology and Medical Microbiology18
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suggested NO therapy can partially enhance the wound 
healing response in a diabetic animal model.
Growth Factor Therapy Stimulates Wound Healing
Concentrations of many growth factors are decreased 
in diabetic wounds. In one model,19 full-thickness skin 
wounds were made in the backs of genetically diabetic 
mice. These wounds were characterized by delayed 
infiltration of inflammatory cells, poor granulation tissue 
formation, and delayed wound closure when compared 
to wounds in nondiabetic littermates. Diabetic wounds 
were treated with recombinant human PDGF and basic 
FGF individually and in combination. Treatment with 
the growth factors resulted in increased fibroblasts and 
capillaries at the wound site and significantly greater 
wound closure after 21 days.
Enhancing VEGF Production in the Diabetic Wound
Enhancing VEGF production in a diabetic wound can 
promote angiogenesis. One group20 used simvastatin, a 
drug typically used to reduce cholestorol, to stimulate 
angiogenesis in a diabetic mouse model. Simvastatin 
was administered daily to diabetic and nondiabetic mice 
with incisional skin wounds. Treatment with simvastatin 
increased VEGF mRNA and protein expression in diabetic 
mice and enhanced NO production, successfully restoring 
wound healing capabilities.
Animal Models of Diabetes Mellitus
Many models exist that accurately portray aspects of both 
type 1 and type 2 diabetes. Type 1 diabetes mellitus 
results from the specific autoimmune destruction of the 
insulin-producing pancreatic beta cells. Hyperglycemia then 
results because there is a lack of or a reduced amount 
of insulin. Type 2 diabetes encompasses a heterogeneous 
group of disorders characterized by insulin resistance 
and impaired insulin secretion. A number of toxins 
can induce type 1 diabetes by damaging pancreatic beta 
cells. Additionally, selective inbreeding has resulted in 
strains that are fairly reasonable models of the disease 
states of type 1 and 2 diabetes and even obesity and 
insulin resistance. Animal models have been instrumental 
in the study of the pathogenesis of diabetes and its 
complications as well as the testing of new diabetic 
treatments before they can be considered for clinical use.58
Animal Models of Type 1 Diabetes Mellitus
Type 1 diabetes mellitus results from the specific auto-
immune destruction of the insulin-producing pancreatic 
beta cells. Subsequently, hyperglycemia results due to 
the lack or reduced amount of insulin.
Surgically and Chemically Induced Type 1 Diabetic 
Animal Models
The effects of hyperglycemia can be studied most simply 
in animals by partial or complete removal of the pancreas. 
Hyperglycemia can also be induced nonsurgically by 
administering toxins such as streptozotocin and alloxan 
that damage the pancreas.59,60 Streptozotocin is a broad-
spectrum antibiotic that has alkylating properties and 
thus modifies biological macromolecules, fragments DNA, 
and destroys the beta cells causing a state of insulin-
dependent diabetes. The drug can be administered intra-
venously or intraperitoneally in a single, large dose or 
smaller, repeated doses over a period of days. A single 
large dose (60 mg/kg) of streptozotocin is sufficient to 
produce diabetes in rodents, although repeated smaller 
doses are equally effective and in fact, may produce 
consistent models more reliably. Both surgically and 
chemically induced pancreatic damage are useful 
in investigating what complications arise because of 
hyperglycemia. For example, the multiple low-dose 
streptozotocin model has been used to investigate the 
immunological pathways that lead to insulitis and beta cell 
death, and both methods performed on female animals 
are helpful in studying the effect of gestational diabetes 
on offspring.58
Spontaneous Animal Models of Type 1 Diabetes
Certain animal strains spontaneously develop diseases 
that are similar to type 1 diabetes. These models are 
produced by selectively inbreeding for generations based 
on hyperglycemia. Inbreeding results in the enrichment 
of a variety of genes and phenotypes, which may differ in 
relevancy to the pathophysiology of diabetes in animals 
or humans. Two of the most common spontaneous models 
for type 1 diabetes are the nonobese diabetic (NOD) 
mouse and the biobreeding (BB) rat because they 
spontaneously develop diabetes similarly to humans.58 
Nevertheless, new animal models are continuously being 
developed because of the inability of a single model to 
completely represent the human disease.
The NOD Mouse
Diabetes in NOD mice develops rapidly; inflammation of 
beta cells due to infiltration of mononuclear cells occurs 
at approximately 4–5 weeks of age. Ensuing destruction 
of the beta cells and decreasing insulin concentrations 
lead to the presentation of frank diabetes within 12 
to 30 weeks. The NOD mouse model has been used 
extensively in diabetes research because similarly to 
humans, the mouse major histocompatibility complex 
(MHC) region largely influences the development of 
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disease.58 As an indication of the importance of genetic 
heterogeneity, the NOD model consists of many genes 
related to susceptibility to autoimmunity.61 However, 
the model differs from human type 1 diabetes in that 
ketoacidosis is generally mild in NOD mice. While these 
mice can survive for extended periods of time without 
the administration of insulin, ketoacidosis is a serious 
condition in humans that can result in diabetic coma or 
death if left untreated. Additionally, the gender difference 
of animals developing diabetes does not reflect the findings 
of human studies.58 Studies involving NOD mice have 
focused on cell apoptosis in diabetic wounds and the 
immunological cascade consisting of T-helper type 2 cells 
and effector cells and the contribution of cytokines.30,58
The BB Rat
Several strains of the BB rat exist, although only some are 
diabetes prone. For strains that develop diabetes, weight 
loss, hyperglycemia, and other diabetic complications occur 
at approximately 12 weeks of age. Similarly to NOD mice,
inflammation of pancreatic beta cells induces an auto-
immune response and recruitment of T cells, B cells, 
macrophages, and natural killer cells. More in common 
with humans, however, ketoacidosis in the BB rat is 
severe and fatal in the absence of administered insulin. 
The BB rat has been used in diabetic research to 
investigate the role of diet and a variety of viruses as 
possible environmental stimuli for the disease state.58
Animal Models with Specific Known Mutations or Pathway 
Defects
In certain cases, specific known mutations or pathway 
defects influence the development of type 1 diabetes 
and other autoimmune diseases. Animal models with 
such defects can be used to better understand pathways 
in human disease. Animals that exhibit specific defects 
in genes encoding important tolerance mediators, for 
example, can give insight into the role of these genes 
in humans.61
Humanized Mouse Models
Humanized mouse models of type 1 diabetes are 
produced by introducing genes encoding MHC, T-cell 
antigen receptors, and costimulatory molecules from 
humans. Specific aims of such models include modeling 
disease initiation and evaluating in vivo immuno-
modulation by specific antigens presented in the context 
of humanized MHC and other genes.61–63 Unfortunately, 
humanized mouse models struggle to reproduce human 
diabetes effectively in the animal, particularly when 
human gene products interact with ECM and tissues 
that are not humanized.61
Animal Models of Type 2 Diabetes Mellitus
Type 2 diabetes encompasses a heterogeneous group 
of disorders characterized by insulin resistance and 
impaired insulin secretion. This heterogeneity has led to 
a variety of animal models attempting to address the many 
facets of a complex disease. While some animal models 
emphasize insulin resistance, others predominately exhibit 
beta cell failure resulting in impaired insulin secretion. 
Different models will be more or less clinically relevant 
and extrapolation of results to the clinical setting must 
be undertaken cautiously.
Spontaneous Animal Models of Type 2 Diabetes
The Kyoji Kondo (KK) Mouse
Originally bred for large body size, this animal strain 
develops obesity and insulin resistance that is followed 
by mild hyperglycemia. The severity of the diabetic 
phenotype is highly dependent on food intake, and the 
model is useful in researching human obesity. However, 
multiple strains of KK mice exist because of specific 
inbreeding or spontaneous mutations that are genetically 
and phenotypically different.58
The Goto-Kakizaki (GK) Rat
The GK rat exhibits both insulin resistance and impaired 
insulin secretion having developed relatively stable 
hyperglycemia upon reaching adulthood. This model 
is useful for investigating some complications of diabetes 
as the rats develop renal lesions,62 structural changes in 
peripheral nerves,63 and retinal abnormalities64 similarly 
to humans.58
Single Gene Mutation Animal Models of Type 2 
Diabetes
The Zucker (fa/fa) Rat
Obesity is generally a fair predictor of type 2 diabetes 
in humans. Thus, animal models of obesity have been 
developed in hopes of gaining insight into the disease. 
The Zucker rat is an obese strain that maintains normal 
blood glucose levels by counteracting insulin resistance 
with increased insulin secretion from pancreatic beta 
islet cells.58
The db/db Mouse
In contrast to the Zucker rat, the db/db mouse strain 
fails to maintain the levels of insulin secretion necessary 
for normal blood glucose levels and thus quickly 
develops hyperglycemia.58 The db/db mouse exhibits 
excessive eating, obesity, and elevated blood glucoses of 
300–500 mg/dl caused by a defect in the leptin receptor. 
Similar to the human condition, the mouse has a reduced 
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ability to heal standard skin wounds in addition to 
decreased epidermal nerves.65
Animal Models Resulting from Gene Targeting and 
TransgenicTechniques
Molecular biological techniques such as gene targeting 
have been used to develop new animal models. 
Knockout animals are produced by disrupting single 
genes within an embryonic stem cell. These defects are 
then transmitted along the germ cell line. Additionally, 
transgenic animals are formed when modified genes 
are incorporated into a host genome. Researchers have 
produced models by manipulating various genes, including 
those that encode for insulin receptors or glucokinase. 
Resulting phenotypes include animals that exhibit varying 
degrees of insulin resistance and sensitivity and animals 
with varying blood glucose levels. Complications of these 
techniques arise when gene manipulation produces 
unexpected results. Many genes have different functions 
at various points in an animal’s life and may also 
influence physiological processes not involved in the 
disease process.
Selection of a Diabetic Animal Model
With the variety of animal models representing both 
type 1 and type 2 diabetes, choosing an appropriate 
model for an experimental study requires careful 
consideration. To investigate internal wound healing 
adjacent to medical devices, it should first be determined 
which subset of diabetes is the investigative focus. While 
both type 1 and type 2 diabetic patients will need identical 
implants such as glucose sensors and orthopedic implants, 
the mechanisms leading to the disease state and hyper-
glycemia differ. Type 1 diabetes is most easily produced 
and reproduced by the administration of toxins. The disease 
state requires less time to achieve and dosage can be 
customized to each individual animal. Animals generally 
express diabetes within several days of the last dose of drug. 
Type 2 diabetes is affected by a variety of factors such 
as insulin resistance, impaired insulin secretion, obesity, 
and genetic and environmental factors.58,59,61 Because of 
this variety, investigations often begin with type 1 
animal models. Optimally, studies should be performed 
in a variety of diabetic animal models—representing 
both type 1 and type 2 diabetes—for the purpose of 
comparison and confirmation of data.
Summary
The increasing use of indwelling medical devices and 
the growing population of diabetic patients warrants 
investigation into diabetic wound healing around 
implants. Two of the main reasons for implant failure 
are deficient tissue integration leading to foreign body 
encapsulation and poor tissue integration caused by 
infection. These modes of failure have not been widely 
investigated in diabetic models, and little is known of 
the diabetic response to an indwelling medical device. 
Much of our understanding about wound healing 
in diabetic patients comes from animal experiments 
involving cutaneous wounds and patients with diabetic 
foot ulcers; such information can serve as the basis of 
the investigation of internal diabetic wound healing 
around an implant and the response to implant infection 
in a diabetic model. By quantifying the diabetic 
response to soft tissue implants and infection, diabetic 
wound healing can be better understood and guide 
improvements in implanted device performance.
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